Pharmaceuticals

InMed Pharmaceuticals

InMed Pharmaceuticals released FY2026 Q1 earnings on November 6, 2025 (EST), with actual revenue of USD 1.12 M and EPS of USD -0.4366

InMed Pharmaceuticals Inc. to Hold Annual and Special Shareholders' Meetings on December 17

InMed Pharmaceuticals released FY2025 Q4 earnings on September 23 (EST), actual revenue USD 1.305 M, actual EPS USD -1.1984

InMed Pharmaceuticals released FY2025 earnings on September 23 (EST), actual revenue USD 4.943 M (forecast USD 6.773 M), actual EPS USD -8.3629

InMed Pharmaceuticals Agrees to Stock Sale

InMed Pharmaceuticals Inc. Completes $5 Million Private Placement

InMed Pharmaceuticals Inc. Completes Private Placement Financing for $5 Million

InMed Announces Promising Study Results of Alzheimer's Disease Candidate Drug INM-901

InMed Pharmaceuticals revises standby equity purchase agreement with Yorkville

InMed Pharmaceuticals released FY2025 Q3 earnings on May 12 EST, with actual revenue of USD 1.262 M and EPS of USD -1.9352

InMed Pharmaceuticals released FY2025 9 Months Earnings on May 12 (EST), actual revenue USD 3.638 M, actual EPS USD -8.2854

InMed Pharmaceuticals released FY2025 Q2 earnings on February 12, 2025 (EST) with actual revenue of 1.112 M USD and actual EPS of -3.6445 USD

InMed Pharmaceuticals released FY2025 Semi-Annual Earnings on February 12 (EST) with actual revenue of 2.376 M USD and EPS of -6.4335 USD

InMed Pharmaceuticals Inc. Announces New Formulation for Dry Age-Related Macular Degeneration Treatment

InMed Pharmaceuticals released FY2025 Q1 earnings on November 14, 2024 (EST), with actual revenue of 1.265 M USD and EPS of -2.7056

InMed Pharmaceuticals released FY2024 Annual Earnings on September 30, 2024 (EST): Actual Revenue 4.598M USD (Forecast 5.419M USD), Actual EPS -20.1429 (Forecast -16.0586)

InMed Pharmaceuticals Advances INM-901 Oral Drug for Alzheimer's Treatment, Stock Price Soars 241.8%

InMed Pharmaceuticals released FY2024 9 Months Earnings on May 14 (EST), with actual revenue of 3.315 M USD and EPS of -22.5366 USD

InMed Pharmaceuticals released FY2024 Q2 earnings on February 13 (EST), actual revenue 1.24 M USD (forecast 1.129 M USD), actual EPS -3.7077 USD

InMed Pharmaceuticals released FY2024 H1 earnings on February 13, 2024 (EST), with actual revenue of 2.142 M USD and EPS of -14.2103

Republic Power

Brand Engagement Network

Society Pass

Intelligent Living Application

3 E Network Tech

Globavend

CCSC Tech

Sidus Space

Tryhard

Dreamland

Eli Lilly

Roche

ROCHE HOLDINGS AG

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap